We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes у1500/l, Hb Ͼ 11 g/dl and platelets у100 000/l. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).
Introduction
Despite heterogeneous morphologic, genetic, biologic, and clinical features, all forms of MDS are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. 1 While the ability of the preleukemic stem cell to establish a dominant myelodysplastic clone is most likely attributable to the accumulation of genetic lesions, including gross chromosomal changes as well as point mutations, an abnormal bone marrow microenvironment also plays a role in the pathophysiology of MDS. Microenvironmental factors involve aberrant cytokine production, altered stem cell adhesion, altered angiogenesis, and immunological attack. These abnormalities may provide new therapeutic targets.
Thalidomide is a sedative drug that has both immunosuppressive [2] [3] [4] [5] and anti-angiogenetic properties. 6, 7 Thalidomide has considerable therapeutic efficacy in multiple myeloma, possibly because of its effect on marrow angiogenesis. 8, 9 Since myelodysplastic syndromes have recently been found to be associated with increased marrow angiogenesis 10, 11 and because autoreactive T cells appear to contribute to the bone marrow failure in MDS, 12, 13 we undertook a pilot study to examine whether thalidomide is of therapeutic value for patients with MDS.
Materials and methods

Patients
Between July 1999 and June 2001, 34 patients with MDS received thalidomide ( Table 1 ). According to FAB criteria 14 the diagnoses were RAEB-T (five), RAEB (four), CMML (three), RARS (six) and RA (16) . One patient with RARS was diagnosed as having secondary MDS resulting from treatment with methotrexate over a period of 7 years because of rheumatoid arthritis. The median duration of MDS before entry into the study was 30 months (range 6-144 months). All patients gave written informed consent to the treatment with thalidomide.
The study was performed according to the standards of the Ethics Committee of the Medical Faculty of our university. The median age of the patients was 67 years (range 54-83). There were 18 males and 16 females. Cytogenetic analyses showed 12 normal karyotypes, four cases with del(5q−), 15 complex abnormal karyotypes and three single aberrations according to the International Prognostic Scoring System. 15 Using the IPSS, there were four patients with low-risk, 14 patients with intermediate-1-risk, nine patients with intermediate-2-risk and seven patients with high-risk MDS.
Three patients with RA had been pretreated with antilymphocyte globulin (ALG) without improvement of peripheral blood counts. ALG had been administered 8, 12 and 16 months, respectively, before starting thalidomide. Two patients with RAEB had been treated intensively with idarubicin, etoposide and cytarabine in 1997 and 1998; thalidomide was started in March 2000 and August 2000. Five patients (three RA, one RARS, one RAEB-T) with a low erythropoetin level (Ͻ200 mU/ml) had been treated for 3 months with erythropoetin (3 × 10 000 IU/week) without improvement of hemoglobin, 6, 9 and 10 months before thalidomide was started. All other patients with anemia in our study showed an increased erythropoetin-level (median Ͼ400 mU/ml), so that treatment with erythropoetin was not tried.
At the time of enrollment, 26 patients had either transfusiondependent anemia, transfusion-dependent thrombocytopenia, or granulocytopenia Ͻ500/l. Eight patients showed either a reduction in hemoglobin concentration by at least 2 g/dl or a 50% or greater decrement in granulocytes or platelets during a 3-month period before starting thalidomide.
Thalidomide
Thalidomide in 100 mg capsules was provided by Grü nenthal (Aachen, Germany) on a compassionate-use basis. The drug was administered once a day in the evening, starting with 100 mg/day. The dose was gradually increased by 100 mg/day every week, until hematological improvement was observed or adverse events occurred. An effective and well tolerated 
Laboratory evaluation
Pretreatment evaluation included complete blood count, differential blood count, erythropoetin, T lymphocyte subpopulations (CD3, CD4, CD8) and tests of renal and liver function. Bone marrow aspirates were obtained to determine dysplastic morphologic features and percentage of blasts in the bone marrow, and to identify karyotypic abnormalities. Follow-up studies included weekly blood counts and tests of renal and liver function. If possible, bone marrow was re-examined at the time of maximal hematologic response or when patients discontinued thalidomide because of side effects.
Treatment responses were classified according to the criteria proposed by an international working group (IWG criteria). 16 A complete remission was defined as hemoglobin Ͼ11 g/dl, thrombocytes Ͼ100 000/l and granulocytes у1500/l for a period of 8 weeks at a stable dose of thalidomide without dysplasia in the bone marrow. Partial remission was defined as Hb Ͼ11 g/dl, Thr у100 000/l, granulocytes у1500/l, but persistence of dysplastic abnormalities in the bone marrow. Hematologic improvement (HI) presenting as major erythroid response was defined as an increase in hemoglobin greater than 2 g/dl in patients with a pretreatment hemoglobin less than 11 g/dl, a minor response being an increase in hemoglobin 1-2 g/dl. Major platelet response means an absolute increase in platelets of 30 000/l or more; minor response was defined as an increase greater than 10 000/l but less than 30 000/l. Major neutrophil response was defined as an absolute increase in neutrophils of more than 500/l, minor response showed an ANC increase of at least 100%, but an absolute increase less than 500/l. Stable disease (SD) means neither signs of hematological improvement nor evidence of progression for at least 2 months.
Results
Twenty-nine of 34 patients who received thalidomide were evaluable for response. Four patients discontinued the drug at a dose level between 200 mg and 300 mg because of sideeffects. One patient with RA (No. 33) died after 4 weeks of thalidomide, probably due to heart failure. He showed neither signs of progressive disease nor hematologic improvement. One patient (No. 10) developed a severe skin rash after 2 weeks on thalidomide, while in three patients (Nos 1, 24 and 32) intolerable fatigue was the reason for discontinuing thalidomide after a median time of 4 weeks. The median thalidomide dosage in our patient population was 400 mg/day (25/34 patients). On 400 mg/day thalidomide, it took about 2 months until hematologic improvement occurred.
Four patients showed neither hematologic improvement nor progressive disease (stable disease) on thalidomide at a daily dose of 400 mg/day and discontinued the drug after a median of 6 months. Two of these patients (Nos 13 and 34) with RA had a complex karyotype prior to thalidomide. Bone marrow aspiration showed persistent dysplastic changes. Cytogenetic analysis yielded no additional abnormalities. One patient (No. 13) had already received an unsuccessful trial of immunomodulatory treatment with ALG.
The other two patients with stable disease (No. 9, RAEB-T and No. 27, RA), had a normal karyotype and an intermediate karyotype, respectively.
Six patients (four RA, two CMML) showed a failure of thalidomide treatment, with progressive disease after a median duration of treatment of 3 months (2-4) at a daily dose of 400 mg/day. In five of these patients, transformation to AML occurred. One patient with RA (No. 22) showed an increase of bone marrow blasts to 10% after 2 months of thalidomide, thus progressing to RAEB. Three of the six patients (one CMML, two RA) had a complex karyotype, while the other three patients showed a normal karyotype. Thalidomide was discontinued in the six patients, who then received chemotherapy with idarubicin, cytarabine or gemcitabine.
In the responding 19 patients, thalidomide has been administered for a median time of 10 months (range 5-17) at a median dose of 400 mg (200-500 mg). The earliest therapeutic benefit was noted 6 weeks after the start of treatment. In the majority of patients, however, it took at least 8 weeks until hematological improvement occurred.
The responses included nine partial remissions (three RA, one RARS, two RAEB and three RAEB-T). The clinical courses of the nine patients are shown in Figure 1 . All patients achieved a normal peripheral blood count, and three of four patients with high-risk MDS achieved a normal blast count in the bone marrow. They were not classified as complete remissions because bone marrow cytology showed persistent dysplastic abnormalities, eg ring-sideroblasts or micromegaka-
Figure 1
Clinical courses of patients achieving partial remission.
Leukemia Table 2 Responses to thalidomide according to the FAB subtype PR Major Minor SD PD response response RA (n = 14) 3 5 (2 × HI-E + 3 3 HI-P, 1 × HI-E + HI-N, 2 × HI-E) RARS (n = 4) 1 1 (HI-E + HI-1 (HI-E) 1 P + HI-N) RAEB (n = 3) 2 1 (HI-E + HI-P) RAEB-T (n = 5) 3 1 (HI-E + HI-P) 1 CMML (n = 3) 1 (HI-P) 2 PR, partial remission; SD, stable disease; PD, progressive disease; HI-E, erythroid response; HI-P, platelet response; HI-N, neutrophil response.
ryocytes. The responders have now been in remission for a median duration of 10 months (range 6-18). In remission, the daily dose of thalidomide was reduced to a median of 200 mg/day. Two patients with RAEB-T (Nos 11 and 29), who achieved partial remission with Hb Ͼ11 g/dl, thrombocytes Ͼ100 000/l, neutrophils Ͼ1500/l and normal blast count in the bone marrow, relapsed after a remission duration of 8 and 16 months, respectively, while still receiving thalidomide at a dose of 400 mg/day and 200 mg/day.
Four patients (RARS (No. 26), RAEB (No. 28), RAEB-T (No. 21), CMML (No. 25))
, showed a major erythoid, neutrophil and/or platelet response, achieving transfusion independence. Six patients (five RA, one RARS) showed a minor response with a significant decrease in their transfusion requirements (more than 50%) (Tables 2 and 3 ).
The therapeutic benefit for the responding patients was significant since most of them had been transfusion dependent, requiring a median of 7 units of packed red cells (range 4-12) and five platelet transfusions (range 6-24) during the 3-month period before entry into the study. Since infectious complications had not been a frequent problem for the majority of the responding patients, the increase in neutrophil counts did not immediately translate into a measurable clinical benefit. However, it is reasonable to assume that the likelihood of severe infections has decreased.
The hematological improvements were associated with changes in the cytomorphology of the bone marrow. For instance, the six responders (Nos 3, 4, 11, 19, 21, 29) who had had an increased proportion of blast cells in the bone marrow (median 22%) showed a significant decrease to 8% Table 3 Responses to thalidomide according to the IPSS subgroup IPSS subgroup PR Major Minor SD PD (n = 29) response response
HI-P, 2 × HI-E, 1 × HI-E + HI-N) Intermediate-2 3 1 (HI-E + HI-P) 1 3 (n = 8) High (n = 7) 4 2 (HI-E + 1 HI-P + HI-N, HI-E + HI-P) PR, partial remission; SD, stable disease; PD, progressive disease; HI-E, erythroid response; HI-P, platelet response; HI-N, neutrophil response.
Table 4
Responses to thalidomide according to the cytogenetic subgroup Cytogenetic PR Major Minor SD PD subgroup (IPSS) response response (n = 29) good (n = 13) 5 1 (HI-P) 3 (HI-E + HI-P, 1 3 HI-E, HI-E + HI-N) Intermediate 1 (HI-E + HI-P) 1 (n = 2) Poor (n = 14) 4 3 (HI-E + 2 (2 × HI-E) 2 3 HI-P + HI-N, 2 × HI-E + HI-P) PR, partial remission; SD, stable disease; PD, progressive disease; HI-E, erythroid response; HI-P, platelet response; HI-N, neutrophil response.
blasts (median) after 3 months of thalidomide. Nevertheless, dysplastic features like pseudo-Pelger cells or hypogranular myelocytes were still detectable. In five of 10 patients who were evaluable, bone marrow cellularity had increased after a 3-month period of thalidomide treatment. One patient showed decreased cellularity after thalidomide, while four patients showed normal cellularity before thalidomide as well as after a 3-month period of treatment. Dysplastic features did not change significantly: while the number of megakaryocytes increased during thalidomide treatment, micromegakaryocytes or mononuclear megakaryocytes persisted. While the erythroid:myeloid ratio in the bone marrow increased, dysplastic features like nuclear lobulation or multinuclearity remained essentially unchanged. The response to thalidomide was not associated with a particular karyotype (Table 4) . Among 19 patients achieving hematologic improvement, nine patients had complex aberrations, one patient showed a single aberration, and nine patients had a normal karyotype or a 5q− anomaly. Only one patient (RAEB-T) with a complex karyotype, who achieved partial remission, also showed a major cytogenetic response according to the IWG criteria. 16 All other responding patients showed neither a cytogenetic response nor additional cytogenetic abnormalities during thalidomide treatment.
The clinical course of one of the responders is shown in Figure 2 . This patient (No. 7) had suffered from MDS (RA) for
Figure 2
Hematological response to thalidomide treatment, patient No. 7 1 year. The pancytopenia had been refractory to immunmodulatory treatment with ALG. A trial of danazol had also been unsuccessful. Since his Epo level was increased to 600 mU/ml (normal range 1.6-29.5 mU/ml), treatment with erythropoetin was not tried. During the months prior to thalidomide he had received red cell transfusions weekly and platelet transfusions twice weekly. Thalidomide was started in February 2000. He became transfusion-independent within 2 months and the hematological response (partial remission) is ongoing at the time of writing.
Adverse effects
Side-effects were observed in all patients. The incidence of adverse effects at different dose levels is shown in Table 5 . Adverse effects were usually mild or moderate (grade 1 or 2 according to Common Toxicity Criteria). The most common side-effects were fatigue (35%) and obstipation (32%). Three patients could not tolerate thalidomide because of fatigue and discontinued treatment after 3 or 4 weeks. Three patients had mild peripheral edema which did not require treatment with diuretics. There were no signs of nephrotoxicity or liver toxicity. Deep venous thrombosis in the leg occurred in two patients after 2 and 4 months, respectively, on thalidomide treatment. Both patients received a thalidomide dose of 400 mg/day. Another patient, with a previous history of allergic reactions, developed a skin rash with bullous lesions after 2 weeks of thalidomide at a dose of 200 mg/day. Thalidomide was discontinued and the skin lesions disappeared within 2 weeks. Three patients developed mild peripheral neuropathy, which was reversible after dose reduction of thalidomide.
Discussion
In this report we show that thalidomide has considerable efficacy in the treatment of patients with MDS. Nineteen out of 29 evaluable patients achieved hematological improvement, including nine partial hematological remissions with granulocytes у1500/l, Hb Ͼ11 g/dl and thrombocytes у100 000/l. The responding patients became transfusion independent within a treatment period of 2 months. In two of these patients it was possible to discontinue the iron-chelating therapy for preventing hemosiderosis. The 19 responding patients clearly showed an improvement in their quality of life. They prefer the thalidomide treatment to regular transfusion therapy.
Three patients with RA and one patient with RAEB-T did not respond to thalidomide after a treatment period of 6 Two patients with RAEB-T relapsed after a partial remission of 8 and 16 months, respectively. Their thalidomide dose had been reduced from 400 mg/day to 200 mg/day and from 500 mg/day to 300 mg/day, respectively.
Response or failure were not associated with a specific FAB subtype, IPSS risk group or cytogenetic subgroup prior to thalidomide treatment. Thirteen patients achieved platelet and RBC transfusion independence (partial remission + major response). According to the IPSS, six of these patients were classified as high risk, four patients were intermediate-2-risk, one patient was intermediate-1-risk and two patients were low-risk. Although the response rate to thalidomide seems to be higher in patients with high-risk MDS than in patients with low-risk MDS, two relapses occurred among high-risk MDS patients, whereas no patient with low-risk/intermediate-1-risk MDS has relapsed so far.
The improvement in peripheral blood counts was not accompanied by a significant decrease in the proportion of dysplastic cells or in the cellularity in the bone marrow in 10 patients who were evaluable. However, there was a reduction in the proportion of blast cells in the bone marrow of five patients with RAEB or RAEB-T, three patients achieving a normal blast count.
There are some recent reports on thalidomide treatment of myelodysplastic syndromes. [17] [18] [19] [20] [21] Raza et al 19 used thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or enbrel. Fifty-one of 83 patients were evaluable. Most of these patients had RA, RARS and RAEB, and their median age (68 years) was similar to that of our patients. Twenty-one patients achieved a partial remission (41%), whereas no complete remissions were observed. The daily dose of thalidomide was 400 mg/day for 12 weeks. There was no significant decrease in TNF-␣ levels or microvessel density in responders.
Dourado et al 17 reported nine patients (six RAEB-T, two RARS, one CMML). The median dose of thalidomide was 400 mg/day. Six of the nine patients responded (two CR, four PR). Thomas et al 21 reported nine patients (six RAEB, two RAEB-T, one CMML) who received thalidomide at a dose ranging from 200 mg to 800 mg/day. Of the seven evaluable patients, only one responded to thalidomide.
Thalidomide is known as an effective immunomodulatory and anti-inflammatory drug with potential for the treatment of a range of conditions, including HIV and neoplasias. It was also one of the first drugs to show an anti-angiogenetic effect. D'Amato et al 6 demonstrated that orally administered thalidomide is a moderate inhibitor of angiogenesis, as observed in a model of basic-fibroblast growth factor-induced neovascularization in the rabbit cornea micropocket assay. The mechanism of the anti-angiogenetic effect of thalidomide is not understood, but it requires metabolic activation, which is species dependent. 7 However, there was no significant decrease of microvessel density in the bone marrow of patients with multiple myeloma who responded to thalidomide. 8 This argues against an anti-angiogenetic effect as the major mechanism of thalidomide action.
It is also unclear whether the reduction of blast cells that we observed in the bone marrow of high-risk MDS patients is attributable to a cytotoxic effect of thalidomide on the malignant cells or to a modulation of their interaction with the bone marrow microenvironment. Thalidomide modulates adhesive Leukemia interactions 22 and induces changes in the expression level of surface molecules.
In summary, the mechanism of action of thalidomide in MDS is not known, but up to now there is no evidence that its anti-angiogenetic properties or its ability to suppress TNF-␣ production are pivotal.
While it is to be hoped that future studies will contribute to our understanding of thalidomide action as well as MDS pathogenesis, it appears that thalidomide can already be added as an effective new agent to our not very impressive armament for fighting myelodysplastic syndromes.
